Investigational drug · Phase 2
ATR 1072
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cardiac Glycogenosis, Cardiomyopathy, Hypertrophic.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ATR 1072"
First trial start
2026
Sep 14, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ATR 1072", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cardiac Glycogenosis
- Cardiomyopathy
- Hypertrophic
- Wolff-Parkinson-White Syndrome
Approved drugs for the same conditions: Parkinson's disease · Cardiovascular and metabolic · Neurology · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "ATR 1072" as an intervention, largest first.
Atrium TherapeuticsIndustry
NCT07738107 · 37 participants (planned) · Start Sep 14, 2026 · Primary completion May 2028
Drug: ATR 1072 · For: Cardiac Glycogenosis; Cardiomyopathy; Hypertrophic and 1 more
Sites: Kansas City, Missouri; Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.